Treatment of COVID-19 Post-acute Cognitive Impairment Sequelae With tDCS

Study Overview
=================
Brief Summary
-----------------
After almost 2 years of pandemic, the consequences of the post-COVID syndrome, or PASC (Post Acute-Sequelae of Sars-CoV-2), have become a major challenge in the management of affected patients, generating costs for health services. and insecurity regarding treatments for the sequelae, given the complex and still poorly understood pathophysiology of COVID-19. This troubling scenario raises important questions about the impact of COVID-19 on central nervous system sequelae, including the risk of cognitive decline in old age and progression to dementia. Therefore, studies that propose the possibility of treatment for this new clinical condition and that are free from systemic side effects, such as transcranial direct current stimulation (tDCS) and cognitive treatment, are extremely important in the face of this scenario. In addition, the evaluation of the neural mechanisms underlying the cognitive alterations of the PASC syndrome and after the treatment using multimodal magnetic resonance imaging (MRI) becomes relevant in view of the lack of studies related to the topic. Therefore, the objective of this double-blind randomized clinical trial is to assess whether tDCS associated with cognitive training can improve symptoms in patients with persistent cognitive deficits that started between 1 and 6 months after the resolution of acute COVID-19 infection (PASC) compared to the sham (placebo) group, in addition to exploring the structural, microstructural, functional and modeled electric field changes associated with cognitive alterations due to PASC syndrome and tDCS combined with cognitive treatment. 60 patients aged between 18 and 70 years and with a positive diagnosis of mild to moderate COVID-19 in the last 6 months in relation to the time of entry into the study will be recruited. All of them will be pre-screened online and in person to confirm the cognitive dysfunction associated with PASC.

Detailed Description
-----------------
As of August 1, 2021, novel coronavirus disease 2019 (COVID-19), an infection caused by Severe Acute Respiratory Syndrome (SARS-CoV-2), had infected over 200 million people and accounted for more than 4 million deaths worldwide. After remission of the acute phase of the disease, many patients report persistent symptoms that go far beyond the consequences of the pulmonary involvement itself and can impose chronic sequelae of COVID-19. According to the World Health Organization, post-COVID-19 syndrome occurs in individuals with a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and lasting at least 2 months and cannot be explained by an alternative diagnosis. The most common complaints are extreme fatigue, inability to perform activities of daily living that involve physical or cognitive exertion, emotional dysregulation, mental fog, and other symptoms of cognitive impairment. Symptoms may be new after initial recovery from an acute episode of COVID-19 or persist from the initial illness. Symptoms can also fluctuate or recur over time. Given the increasing number of COVID-19 cases, there is an urgent need to develop treatment alternatives for PASC-related cognitive and memory deficits. In this context, transcranial direct current stimulation (tDCS or tDCS) is a non-invasive brain stimulation intervention that may be promising in these cases. It represents an interesting opportunity for targeting the neural circuits underlying neurological, cognitive, and psychiatric disorders. For example, once a target neural circuit has been identified as a related region of interest for a neuropsychiatric disorder, neuromodulation methods could be used to selectively modify activities in the target region. In tDCS, a direct, low-intensity electrical current (e.g., typically 1-4 mA) is passed through at least two electrodes (i.e., anode and cathode), which are applied non-invasively to the scalp. TDCS modulates neuronal activity at the network level by producing current flow around neurons and resulting in an incremental change in neuronal membrane potentials. In turn, such potential changes lead to a series of changes in neuronal function, such as a change in firing rates. Thus, tDCS can induce long-term changes in brain activity. Learning ability requires functional changes that can be induced by tDCS, which makes this technique a promising tool to improve cognitive performance. In fact, tDCS has already been successfully used in non-COVID-19 samples to improve cognitive performance in several domains, such as working memory, episodic memory, executive function, and language. It is also worth noting that tDCS presents definite or probable evidence of efficacy for several neuropsychiatric disorders that are often accompanied by cognitive deficits such as addiction, attention deficit/hyperactivity disorder, Parkinson's disease (motor and cognitive impairment), epilepsy, schizophrenia, Alzheimer's disease, and depression. TDCS has attractive advantages for clinical use, such as affordability, lower cost than magnetic stimulation, ease of use and operation, especially for customized devices, and portability. In fact, the development of portable devices with remote control allows for greater ease of use and feasibility in uncontrolled pandemic scenarios. Furthermore, recent evidence suggests that the effects of tDCS may be enhanced by a concomitantly administered intervention. Neurophysiological studies have shown that tDCS parameters used in clinical practice have an unlikely impact on neural spiking, as such modulation is only achieved at doses ≥ 4.5mA. Rather, the effects of tDCS on behavior are best explained by modulating ongoing activity. According to the selective activity hypothesis, tDCS preferentially modulates a neuronal network that is already activated, rather than separate inactive neuronal networks. For example, in vitro direct current stimulation (DCS) preferentially increased plasticity in a synaptic pathway previously stimulated at 0.1 Hz, whereas DCS alone, without preactivation, did not influence synaptic efficacy. Another study showed that anodic DCS increased long-term potentiation (LTP) induced by high-frequency stimulation, but did not induce LTP per se. In other words, preclinical studies have shown that tDCS is too nonspecific to alter synaptic efficacy alone, but can enhance Hebbian (associative) plasticity activated by task performance. The pupillary light reflex (PLR) is a reflex that controls the diameter of the pupil in response to variations in light intensities that reach the retina and is modulated by the autonomic nervous system (ANS) that innervate the circular and radial muscles of the iris, while contracting or relaxing, decrease or increase the size of the pupil, respectively. Studies have shown that a specific selection of intensity and light stimulus, wavelength and duration directly influence the contributions of retinal photoreceptors, making it possible to also assess retinal changes beyond the ANS. Patients with Alzheimer's Disease (AD) are known to have alterations in cholinergic neurotransmission, in a decrease in pupil diameter response to abrupt changes in room lighting or a single flash of light. Therefore, the RPL is a good tool for evaluating patients with AD. Another potentially relevant change may occur in the regulation of the ANS in the heart rate, which can be measured by checking the heart rate variability (HRV). This type of measurement involves the collection of HR for approximately 5 minutes, allowing measurements in the frequency domain, being separated into two bands: the high frequency, associated with vagal activity, and the low frequency, associated with sympathetic activity. There is evidence that HRV is decreased in several cognitive disorders. Thus, it is reasonable to assume that the HRV may also be altered in the PASC. In fact, a point of convergence between AD and the cognitive sequelae of COVID-19 would be precisely autonomic dysfunction - chronic, progressive and of neurodegenerative etiology in the case of AD, and acute, caused by the inflammatory storm of COVID-19 and its multisystem consequences. Thus, the investigation of this biomarker can help in the understanding of cognitive PASC. MRI assessments have become important in the study of brain structure and function, their respective changes and associations with clinical and neuropsychological assessment scores. Neuroimaging studies on COVID-related pathologies and associations with cognitive changes, in addition to the assessment of the impacts of non-invasive brain stimulation, are embryonic. Reviews of acute and chronic effects have been published, although they are more qualitative in terms of the damage caused, without exploring quantitative markers of brain structure, microstructure and function. Therefore, the present project is a pioneer in identifying alterations in quantitative markers of multimodal MRI, their associations with neuropsychological assessment scores and for evaluating the effects of tDCS combined with cognitive treatment in a group of patients with CSBP. The aim of this double-blind randomized clinical trial is to assess whether tDCS combined with cognitive training can improve symptoms in patients with persistent cognitive deficits that started between 1 and 6 months after resolution of acute COVID-19 infection (PASC or syndrome of long-covid) compared to the sham (placebo) group. In addition, it is aimed to describe the subjective symptoms related to PASC; to assess whether the RPL is altered in patients with post-COVID cognitive impairment and whether it can be used as a biomarker for treatment response; to assess whether HRV is altered in patients with post-COVID cognitive impairment and whether it can be used as a biomarker for treatment response; to evaluate the neural mechanisms underlying the cognitive alterations of the PASC syndrome; and to assess brain changes after tDCS treatment combined with cognitive treatment using multimodal magnetic resonance imaging (MRI).

Official Title
-----------------
Treatment of COVID-19 Post-acute Cognitive Impairment Sequelae (PASC) With Portable Brain Stimulation: a Double-blind, Randomized-controlled Trial

Conditions
-----------------
Cognitive Impairment, COVID-19, Post-Acute Sequelae of SARS-CoV-2 Infection

Intervention / Treatment
-----------------
* Procedure: Active tDCS and cognitive training
* Procedure: Sham tDCS and cognitive training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age from 18 to 70 years; Positive diagnosis (confirmed by RT-PCR nasal swab) of COVID-19 within the last 6 months in relation to the time of assessment; Mild to moderate COVID-19 disease (no hospital stay required); A score above 10 in the cognitive symptoms domain of the Post-COVID-19 Symptom Assessment Questionnaire; Clinical neuropsychological assessment/neurological examination indicating cognitive impairment after acute COVID illness. Exclusion Criteria: Contraindications to the use of tDCS (such as metal plates on the head); Severe acute COVID-19 illness; Less than 8 years of schooling; Presence of serious neurological conditions such as neurocognitive disorders, stroke, lacunar infarction, cerebral atrophy and others; Presence of serious psychiatric disorders, such as untreated mood disorders (including suicidal ideation), personality disorders, or psychotic disorders; Unstable clinical conditions; Use of medications (such as benzodiazepines and anticonvulsants) that can impair cognition; Presence of pathological neuroimaging findings (eg, acute or subacute lacunar or hemorrhagic stroke and others); Presence of a pacemaker, orthosis or prosthesis incompatible with the performance of magnetic resonance imaging; Claustrophobia.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Double-active<br>Active transcranial electrical stimulation and cognitive training. | Procedure: Active tDCS and cognitive training<br>* Electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. Current strenght is set at 2mA for 20 minutes, daily for 5 continuous days (with a 2-day pause) for 4 weeks. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.<br>|
| Sham Comparator: Cognitive training-only<br>Sham transcranial electrical stimulation and cognitive training. | Procedure: Sham tDCS and cognitive training<br>* Sham electrical stimulation is delivered by the Soterix device, consisting of a one-size-fits-all, transcranial direct current stimulation headset with square electrodes. The anode is positioned over the left prefrontal cortex, and the cathode over the right prefrontal cortex. The sham protocol consists of a fade-in and fade-out phases of 1mA for 45 seconds, followed by a silent period in between for the remaining session time. Cognitive training consists of a series of tasks performed in the BrainHQ app, which aim to stimulate the impaired cognitive domains in people with PASC. The cognitive training sessions are performed concomitantly to the tDCS sessions.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in neuropsychological assessment between experimental groups | A battery of neuropsychological tests to assess memory, attention, executive functions and mood. | Week 0 (baseline) and Week 4 (endpoint) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in pupillary reflex | Roland system, composed of a Ganzfeld (Roland Consult), with light-emitting diodes responsible for the stimulus and an infrared camera, capable of recording images in the dark with high spatial and temporal resolution, in continuous recording in recording mode at 30 Hz | Week 0 (baseline) and Week 4 (endpoint) | 
| Brain changes using multimodal magnetic resonance imaging (MRI) | Functional and structural MRI scans | Week 0 (baseline) | 
| Change in heart rate variability (HRV) between experimental groups | Heart rate measure with Polar device | Week 0 (baseline) and Week 4 (endpoint) |